Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker INBX
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Schonfeld Strategic Advisors LLC | 952,959 | 6.5% | SCHEDULE 13G/A ↗ |
| Oct 28, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Bank of America Corp /DE/ | 357,318 | 2.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G | INBX Inhibrx Biosciences, Inc. | Schonfeld Strategic Advisors LLC | 781,678 | 5.3% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Perceptive Life Sciences Master Fund, Ltd. | 1.49M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Joseph Edelman | 1.49M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Perceptive Advisors LLC | 1.49M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Rose Sharon Shabet | 1.38M | 9.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Halvorsen Ole Andreas | 1.38M | 9.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities Drawdown (Aggregator) LP | 80,413 | 0.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities Drawdown Portfolio GP LLC | 80,413 | 0.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities Drawdown GP LLC | 80,413 | 0.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Kavra 104 LLC | 52,392 | 0.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities Illiquid Investments Sub-Master LP | 1.25M | 8.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities Portfolio GP LLC | 1.25M | 8.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities GP LLC | 1.30M | 8.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities Parent GP LLC | 1.38M | 9.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Investors LP | 1.38M | 9.3% | SCHEDULE 13G/A ↗ |
| Aug 3, 2026 | SCHEDULE 13G | INBX Inhibrx Biosciences, Inc. | Bank of America Corp /DE/ | 857,318 | 5.9% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Perceptive Life Sciences Master Fund, Ltd. | 1.46M | 10.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Joseph Edelman | 1.46M | 10.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Perceptive Advisors LLC | 1.46M | 10.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Rose Sharon Shabet | 1.46M | 10.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Halvorsen Ole Andreas | 1.46M | 10.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities Drawdown (Aggregator) LP | 102,864 | 0.7% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities Drawdown Portfolio GP LLC | 102,864 | 0.7% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities Drawdown GP LLC | 102,864 | 0.7% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Kavra 104 LLC | 67,018 | 0.5% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities Illiquid Investments Sub-Master LP | 1.29M | 8.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities Portfolio GP LLC | 1.29M | 8.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities GP LLC | 1.36M | 9.3% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities Parent GP LLC | 1.46M | 10.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Investors LP | 1.46M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Rose Sharon Shabet | 1.45M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | David C. Ott | 1.45M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Halvorsen Ole Andreas | 1.45M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities Drawdown (Aggregator) LP | 102,864 | 0.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities Drawdown Portfolio GP LLC | 102,864 | 0.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities Drawdown GP LLC | 102,864 | 0.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Kavra 104 LLC | 67,018 | 0.5% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities Illiquid Investments Sub-Master LP | 1.28M | 8.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities Portfolio GP LLC | 1.28M | 8.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities GP LLC | 1.35M | 9.3% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Opportunities Parent GP LLC | 1.45M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | Viking Global Investors LP | 1.45M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 11, 2026 | SCHEDULE 13G | INBX Inhibrx Biosciences, Inc. | Morgan Stanley Capital Services LLC | 918,011 | 6.3% | SCHEDULE 13G ↗ |
| Feb 11, 2026 | SCHEDULE 13G | INBX Inhibrx Biosciences, Inc. | Morgan Stanley | 1.16M | 7.9% | SCHEDULE 13G ↗ |
| Jan 21, 2026 | SCHEDULE 13G | INBX Inhibrx Biosciences, Inc. | BlackRock, Inc. | 768,130 | 5.3% | SCHEDULE 13G ↗ |
| Oct 17, 2025 | SCHEDULE 13G/A (amended) | INBX Inhibrx Biosciences, Inc. | BlackRock, Inc. | 680,368 | 4.7% | SCHEDULE 13G/A ↗ |
| Feb 26, 2025 | SCHEDULE 13D/A (amended) | INBX Inhibrx Biosciences, Inc. | Jon Faiz Kayyem | 1.15M | 7.9% | SCHEDULE 13D/A ↗ |
| Feb 26, 2025 | SCHEDULE 13D/A (amended) | INBX Inhibrx Biosciences, Inc. | The Jon F. Kayyem and Paige Gates-Kayyem Family Trust | 509,360 | 3.5% | SCHEDULE 13D/A ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 10:45 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances